ZOLEDRONIC ACID - Z 4 MG / 5 ML
ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) : 4 MG / 5 ML · DIN 02401606 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is ZOLEDRONIC ACID - Z?
ZOLEDRONIC ACID - Z 4 MG / 5 ML contains ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) : 4 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02401606, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 15-Jan-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZOLEDRONIC ACID - Z used for?
Treatment of Tumour-Induced Hypercalcemia (cCa ≥ 12.0 mg/dL); bone metastases of solid tumours and osteolytic lesions of multiple myeloma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02401606 |
|---|---|
| Brand name | ZOLEDRONIC ACID - Z |
| Generic / active ingredient | ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) : 4 MG / 5 ML |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 4 MG / 5 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | M05BA08 ZOLEDRONIC ACID |
| AHFS class | 92:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Jan-2014 |
| Original market date | 2014-01-15 00:00:00 |
How is it administered?
4 mg via IV infusion over at least 15 minutes. For bone metastases with renal impairment, lower doses are recommended. Patients must be adequately hydrated.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to STORAGE AND STABILITY section).
How is it supplied?
4 mg/5 mL concentrate (specific container details not in provided text snippet).
Contraindications
Hypersensitivity to zoledronic acid/bisphosphonates; non-corrected hypocalcaemia; pregnancy and breastfeeding.
Warnings and precautions
Risk of Osteonecrosis of the Jaw (ONJ), deterioration in renal function (may progress to failure), and severe hypocalcaemia. Single doses must not exceed 4 mg.
Is ZOLEDRONIC ACID in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M05BA08 ZOLEDRONIC ACID. 9 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACLASTA | 5 MG / 100 ML | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02269198 |
| JAMP-ZOLEDRONIC ACID | 4 MG / 5 ML | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02482525 |
| TARO-ZOLEDRONIC ACID CONCENTRATE | 4 MG / 5 ML | SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02415186 |
| ZOLEDRONIC ACID FOR INJECTION | 4 MG / 5 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02434458 |
| ZOLEDRONIC ACID FOR INJECTION | 4 MG / 5 ML | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02472805 |
| ZOLEDRONIC ACID FOR INJECTION CONCENTRATE | 4 MG / 5 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02422425 |
| ZOLEDRONIC ACID INJECTION | 5 MG / 100 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02422433 |
| ZOMETA CONCENTRATE | 4 MG / 5 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02248296 |
| ACT ZOLEDRONIC ACID | 5 MG / 100 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | DIN 02408449 |
| ACT ZOLEDRONIC ACID CONCENTRATE | 4 MG / 5 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | DIN 02408325 |
Who else supplies ZOLEDRONIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ZOLEDRONIC ACID appears in 176 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.